07:00 , Sep 26, 2011 |  BC Week In Review  |  Clinical News

Pennvax-G: Interim Phase I data

Interim data from 11 healthy volunteers in a U.S. cohort of the open-label Phase I RV262 trial showed that Inovio's Pennvax-G vaccine boosted with the modified vaccinia Ankara-Chiang Mai Double Recombinant (MVA-CMDR) virus vector vaccine...
07:00 , Oct 4, 2010 |  BC Week In Review  |  Clinical News

Pennvax-G: Phase Ib started

NIH and the U.S. Department of Defense's Military HIV Research Program (MHRP) began the international Phase Ib RV262 trial in 92 healthy volunteers to evaluate Inovio's Pennvax-G vaccine boosted with the modified vaccinia Ankara-Chiang Mai...
07:00 , May 10, 2010 |  BC Week In Review  |  Clinical News

Biojector 2000: Phase I/II data

Data from a double-blind, Dominican Republican Phase I/II trial in 450 infants ages 6-24 months showed that 0.1 mL Vaxigrip influenza vaccine delivered intradermally via the Biojector 2000 needle-free injection system produced a seroconversion rate...
08:00 , Feb 23, 2009 |  BC Week In Review  |  Clinical News

Influenza DNA vaccine: Final Phase I data

Final data from a double-blind, dose-escalation, U.S. Phase I trial in 100 healthy volunteers showed that 75%-100% of evaluable patients receiving monovalent Vaxfectin-formulated H5N1 pandemic influenza DNA vaccines had H5 T cell responses. In patients...
07:00 , Jul 21, 2008 |  BC Week In Review  |  Clinical News

Influenza DNA vaccine: Preliminary Phase I data

Preliminary data from a double-blind, placebo-controlled, U.S. Phase I trial in 100 healthy volunteers showed that the company's influenza vaccines were well tolerated and achieved potentially protective levels of antibody responses in up to 67%...
07:00 , Jun 30, 2008 |  BC Week In Review  |  Clinical News

Influenza DNA vaccine: Completed Phase I enrollment

Vical completed enrollment of 100 patients in a double-blind, placebo-controlled, U.S. Phase I trial evaluating Vaxfectin-formulated DNA vaccine, delivered via syringe or the Biojector 2000 jet injector system. The Biojector 2000 is from Bioject Medical...
07:00 , Jun 2, 2008 |  BC Week In Review  |  Clinical News

Biojector 2000: Phase II started

The Centers for Disease Control and Prevention (CDC) began a Dominican Republican Phase II trial to evaluate Vaxigrip influenza vaccine delivered intradermally via Biojector 2000 or intramuscularly via syringe in infants aged 6-23 months. sanofi-aventis...
08:00 , Dec 10, 2007 |  BC Week In Review  |  Clinical News

Influenza DNA vaccine: Phase I expanded

VICL expanded an ongoing double-blind, placebo-controlled Phase I trial to evaluate Vaxfectin-formulated DNA vaccine delivered via syringe or the Biojector 2000 jet injector system. The study already has enrolled 60 healthy volunteers who have received...
07:00 , Oct 8, 2007 |  BC Week In Review  |  Clinical News

Fuzeon enfuvirtide regulatory update

ROG and TRMS withdrew an sNDA for the inclusion of the Biojector 2000 (B2000) needle-free injection device as an administration option for Fuzeon enfuvirtide based on an assessment of the clinical program and the amount...
07:00 , Oct 8, 2007 |  BioCentury  |  Finance

Ebb & Flow

MannKind...